About the Study: This cross-sectional study examines trends in cancer medicine approvals by the US Food and Drug Administration (FDA) for adult solid tumors between 2006 and 2025, including both original and supplemental indication approvals.
Corresponding Author: Bishal Gyawali, MD, PhD, Division of Cancer Care and Epidemiology, Sinclair Cancer Research Institute, Queen’s University, 10 Stuart St, Level 2, Kingston, ON K7L 3N6, Canada (gyawali.bishal@queensu.ca).
10.1001/jama.2026.12089
To access the embargoed study: Visit our JAMA Network Media Center website at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Journal
JAMA